(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
1 March 2012 (01.03.2012)

PCT

(10) International Publication Number
WO 2012/027328 A2

(51) International Patent Classification:
C07K 16/28 (2006.01) *A61K 39/395* (2006.01)
C12N 15/13 (2006.01) *A61P 35/00* (2006.01)

(21) International Application Number:
PCT/US2011/048752

(22) International Filing Date:
23 August 2011 (23.08.2011)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
61/375,999 23 August 2010 (23.08.2010) US
61/380,827 8 September 2010 (08.09.2010) US

(71) Applicant *(for all designated States except US)*: **BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM** [US/US]; 201 West 7th Street, Austin, TX 78701 (US).

(72) Inventors; and
(75) Inventors/Applicants *(for US only)*: **LIU, Yong-Jun** [US/US]; 2623 West Bainbridge Circle, Pearland, TX 77584 (US). **VOO, Kui Shin** [MY/US]; 2207 Drake Falls, Pearland, TX 77584 (US). **BOVER, Laura** [AR/US]; 4522 Brookren Court, Pearland, TX 77584 (US). **TSURUSHITA, Naoya** [JP/US]; 3719 Redwood Circle, Palo Alto, CA 94306 (US). **TSO, J. Yun** [US/US]; 445 Oak Grove Avenue #16, Menlo Park, CA 94025 (US). **KUMAR, Shankar** [US/US]; 3930 Kral Place, Pleasanton, CA 94588 (US).

(74) Agent: **NIELSEN IP LAW LLC**; Nieisen IP Law LLC, 1177 West Loop South, Suite 1600, Houston, TX 77027 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PE, PG, PH, PL, PT, QA, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*

— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*

— *of inventorship (Rule 4.17(iv))*

Published:

— *without international search report and to be republished upon receipt of that report (Rule 48.2(g))*

— *with sequence listing part of description (Rule 5.2(a))*

(54) Title: ANTI-OX40 ANTIBODIES AND METHODS OF USING THE SAME

(57) Abstract: Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or antibody portions, are useful for modulating receptor activity, e.g., in a human subject suffering from a disorder in which OX40 activity is detrimental. Nucleic acids, vectors and host cells for expressing the recombinant human antibodies are provided, and methods of synthesizing the recombinant human antibodies, are also provided.

WO 2012/027328 A2